Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation

Documenti analoghi

• Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome
  di: McDonnell, Thomas C R, et al.
  Pubblicazione: (2018)
• Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I
  di: McDonnell, Thomas, et al.
  Pubblicazione: (2018)
• Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome
  di: Pericleous, Charis, et al.
  Pubblicazione: (2016)
• Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.
  di: Charis Pericleous, et al.
  Pubblicazione: (2016-01-01)
• Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome
  di: Cousins, Laura, et al.
  Pubblicazione: (2015)